Raji Hussein Al-Hadithi
Research Subjects
Raji Hussein Al-Hadithi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alauldeen Mudhafar Zubair Alqasim
Department of Hematology Sultan Qaboos University Hospital Muscat Oman
1 shared publication - Aseel Nashaat Al-Khalidi
Department of Hematology, Teaching Laboratories, Medical City, Baghdad, Iraq
1 shared publication Ismail I. Matalka
Department of Pathology, King Abdullah University Hospital & Faculty of Medicine, Jordan University of Science and Technology, PO Box 630001, Irbid 22110, Jordan. Tel. +962 (2) 7200626. Fax. +962 (2) 7200626. drraji52{at}yahoo.com
1 shared publication- Mohammed Alorjani
Department of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
1 shared publication - Samir Al Bashir
Department of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan
1 shared publication
Latest Publications
- Open Access
- 1 January 2019
- Published by Wolters Kluwer Health in Hematology/Oncology and Stem Cell Therapy
- Vol. 12 (1) , 67-69
Coagulopathic side effect of L-asparaginase on fibrinogen level in childhood acute lymphoblastic leukemia during induction phase
Background: L-asparaginase is chemotherapeutic agent commonly used in treatment of Acute Lymphoblastic Leukemia. Thromboembolic and to a lesser extent bleeding events are serious complications associated with administration of this drug during the induction phase in ALL especially in children resulting from reduced synthesis of proteins such as Antithrombin & fibrinogen. Objective: Evaluation of the coagulopathic side effect of L-asparaginase during the induction phase in treatment of ALL in children by measuring fibrinogen levels before & after administration of this drug. Subjects & method: An interventional prospective study was performed on 30 newly diagnosed children with ALL, all of them received 9 cycles of L-asparaginase during the induction phase according to UKALL 2003 Protocol. Fibrinogen was measured before & after treatment with L-asparaginase and the results are compared to a control group of 30 healthy children age & sex matched. Results: Reduced fibrinogen level is observed in 13 out of 30 patients (43.3%) after treatment with L-asparaginase ranging from 25 to 110 mg/dl with means fibrinogen before & after treatment of 252 ± 16.40 mg/dl & 158.97 ± 17.88 mg/dl respectively (p < .0001). Conclusion: Significant reduction in fibrinogen level occurred in childhood ALL patients after treatment with L-asparaginase.
- 1 January 2019
- Published by Wolters Kluwer Health in Hematology/Oncology and Stem Cell Therapy
- Vol. 12 (1) , 67-69
Open AccessCoagulopathic side effect of L-asparaginase on fibrinogen level in childhood acute lymphoblastic leukemia during induction phase
Background: L-asparaginase is chemotherapeutic agent commonly used in treatment of Acute Lymphoblastic Leukemia. Thromboembolic and to a lesser extent bleeding events are serious complications associated with administration of this drug during the induction phase in ALL especially in children resulting from reduced synthesis of proteins such as Antithrombin & fibrinogen. Objective: Evaluation of the coagulopathic side effect of L-asparaginase during the induction phase in treatment of ALL in children by measuring fibrinogen levels before & after administration of this drug. Subjects & method: An interventional prospective study was performed on 30 newly diagnosed children with ALL, all of them received 9 cycles of L-asparaginase during the induction phase according to UKALL 2003 Protocol. Fibrinogen was measured before & after treatment with L-asparaginase and the results are compared to a control group of 30 healthy children age & sex matched. Results: Reduced fibrinogen level is observed in 13 out of 30 patients (43.3%) after treatment with L-asparaginase ranging from 25 to 110 mg/dl with means fibrinogen before & after treatment of 252 ± 16.40 mg/dl & 158.97 ± 17.88 mg/dl respectively (p < .0001). Conclusion: Significant reduction in fibrinogen level occurred in childhood ALL patients after treatment with L-asparaginase.
- 1 May 2009
- Published by Armed Forces Medical Services in Saudi Medical Journal
- Vol. 30 (5) , 702-704
Diaphragm disease of the jejunum
Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with the development of diaphragm disease. We report a 73-year-old male patient with this condition who had used NSAIDs for 2 years. He presented with general weakness, syncopal attacks, and a short history of melena. At laparotomy, multiple areas of constricted bowel were found in the resected proximal jejunum. Gross and microscopic examination confirmed diaphragm disease. The relevant literature is reviewed.
- 1 May 2009
- Published by Armed Forces Medical Services in Saudi Medical Journal
- Vol. 30 (5) , 702-704
Diaphragm disease of the jejunum
Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with the development of diaphragm disease. We report a 73-year-old male patient with this condition who had used NSAIDs for 2 years. He presented with general weakness, syncopal attacks, and a short history of melena. At laparotomy, multiple areas of constricted bowel were found in the resected proximal jejunum. Gross and microscopic examination confirmed diaphragm disease. The relevant literature is reviewed.